John Conly

Dr. John Conly, MD, CM, CCFP, FRCPC, FCAHS, FAMMI, FACP, FSHEA, FIDSA, is a specialist in infectious diseases in Alberta, Canada.

Affiliations

Alberta Health Services

Conly is an Infectious Disease / IPC Expert for the COVID-19 Scientific Advisory Group under Alberta Health Services.1)

Alberta Medical Association

Conly received the Medal for Distinguished Service from the Alberta Medical Association for “outstanding personal contributions to the medical profession”.

AMR One Health Consortium

Conly is a Work Package Lead, Principal Investigator, and Executive Committee member of the Antimicrobial Resistance (AMR) One Health Consortium.

Canadian Committee on Antibiotic Resistance

Conly served as Chairman of the Board for the Canadian Committee on Antibiotic Resistance (CCAR).

Canadian Expert Advisory Group on Antimicrobial Resistance

Conly is a member of the Canadian Expert Advisory Group on Antimicrobial Resistance (CEAGAR). Fellow members include Allison McGeer, Scott Weese, and Andrew Morris.2)

Canadian Expert Drug Advisory Committee

Conly served as Vice Chair of the Canadian Expert Drug Advisory Committee (CEDAC).

Canadian Infectious Disease Society

Conly formerly served as President of the Canadian Infectious Disease Society (CIDS).

University of Calgary

Conly is a Professor of Medicine, Microbiology, Immunology & Infectious Diseases, Pathology & Laboratory Medicine in the Department of Medicine (Infectious Diseases), Cumming School of Medicine, University of Calgary, where he is also the former Head of the Department of Medicine.3)

Snyder Institute for Chronic Diseases

Conly is the former Co-Director for the Snyder Institute for Chronic Diseases at the University of Calgary.

W21C

Conly is the Medical Director of W21C, a research and innovation initiative based in the University of Calgary and the Calgary Zone of Alberta Health Services (AHS).4) 5)

It is funded by the Government of Canada through a Western Economic Partnership Agreement (WEPA), and later received funding from Alberta Health and Wellness (AH&W), Alberta Innovates, Alberta Ministry of Jobs, Economy, and Innovation, Western Economic Diversification Canada, and Innovate Calgary.

World Health Organization

Conly is a member of the World Health Organization Advisory Group on Integrated Surveillance of Antimicrobial Resistance. He is overseeing the Calgary study site of the WHO's “Case-control study to assess risk factors for SARS-CoV-2 infection among healthcare workers” under the UNITY Studies project.6)

Relationships with Pharmaceutical Companies

1)
2019-nCoV Scientific Advisory Group. (2021, May 27). Alberta Health Services. https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-sag-terms-of-reference.pdf
2)
Expert Advisory Group on Antimicrobial Resistance (EAGAR) - Membership. (2021, June 11). Government of Canada. https://archive.ph/T5QcZ
3)
John Conly. University of Calgary. Retrieved January 8, 2022, from https://research.ucalgary.ca/amr/people/investigators/john-conly
4)
Dr. John Conly, CM, MD. W21C. Retrieved January 8, 2022, from https://archive.ph/Go60B
5)
About. W21C. Retrieved January 8, 2022, from https://archive.ph/1DFCp
6)
Early investigations protocols. World Health Organization. Retrieved January 9, 2022, from https://archive.ph/5vFGC
7)
McCubbin, K. D., Anholt, R. M., de Jong, E., Ida, J. A., Nóbrega, D. B., Kastelic, J. P., Conly, J. M., Götte, M., McAllister, T. A., Orsel, K., Lewis, I., Jackson, L., Plastow, G., Wieden, H.-J., McCoy, K., Leslie, M., Robinson, J. L., Hardcastle, L., Hollis, A., & Ashbolt, N. J. (2021). Knowledge Gaps in the Understanding of Antimicrobial Resistance in Canada. Frontiers in Public Health, 9. https://doi.org/10.3389/fpubh.2021.726484
8)
Conly, J. M. (2012). Antimicrobial resistance programs in Canada 1995-2010: a critical evaluation. Antimicrobial Resistance and Infection Control, 1(1), 10. https://doi.org/10.1186/2047-2994-1-10
Print/export